Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 2,910 shares at $36.00 ($105K) on 2025-12-15, disclosed to the SEC on 2025-12-16.
Scheduled sale ($105k) by SVP, CHIEF ACCOUNTING OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-11-06 | $2.4M | — | Filing → |